糖尿病足脂蛋白(a)的变化  

作　　者：胡婕[1] 陈新[1] 

机构地区：[1]辽宁沈阳市第四人民医院内分泌科,110031

出　　处：《中国医学文摘（内科学）》2006年第6期567-569,共3页China Medical Abstracts

摘　　要：目的探讨糖尿病足坏疽和非坏疽患者血浆脂蛋白(a)浓度的变化。方法测定糖尿病足坏疽组32例,糖尿病非坏疽组18例和健康对照组20例。所有病人有相似的血糖控制和糖尿病病程。用免疫比浊法测定脂蛋白(a)的水平。结果糖尿病足坏疽组脂蛋白(a)水平(496.8±93.7)mg/L比无糖尿病足坏疽组(182.6±60.2)mg/L和正常对照组(168.3±58.8)mg/L明显增高,后两组脂蛋白(a)水平差异无显著性。结论脂蛋白(a)水平可能与糖尿病足坏疽的病情进展相关。Objective Our aim was to discuss the levels of lipoprotcin （ a ） （Lp（a）） in patients with gangrenous or non-gangrenous diabetic foot lesions. Methods 32 patients with gangrenous foot lesions,18 with non-gangrenous foot lesions and 20 healthy subjects were ineluded in the study. All the patients had similar glyccrnic control and duration of diabetes. The plasma Lp（a） conccntration was measured by irnmunc turbidimctry .Results Diabetic with gangrenous foot lesions had significantly higher Lp（a） levels （496.8± 93.7） mg/L than the patients with non-gangrenous foot lesions （182.6± 60.2） mg/L and hcalthy subjects （168.3± 58.8） mg/L.Lp（a） levels were not significantly different in healthy subjects and patients with non-gangrenous foot lesions. Conclusions Lp（a） levels may bc related to the development of gangrenous foot lesions in patients with diabetes mcllitus.

关 键 词：糖尿病 足病变 脂蛋白(a) 

分 类 号：R587.1[医药卫生—内分泌]